China pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says

By Andrew Silver

Tue, May 26, 2026 astatine 6:51 AM CDT 1 min read

By Andrew Silver

SHANGHAI, May 26 (Reuters) - China's booming pharmaceutical manufacture is not being impacted by Beijing's ‌tightening scrutiny implicit deals involving delicate technologies, ‌the CEO of JW Therapeutics said Tuesday.

Global drugmakers are stepping up ​their hunt for China‑developed experimental medicines arsenic they chopped costs up of patent expirations, with manufacture analysts predicting biotech licensing deals would surge to a caller grounds ‌this year.

But past month, ⁠China ordered U.S. tech elephantine Meta to unwind its $2 billion-plus acquisition of AI startup ⁠Manus, arsenic Beijing tightens scrutiny of U.S. concern successful home firms processing frontier technologies, sending a chill crossed ​wider industries.

"For ​us, everything is concern ​as usual. Our cross-border ‌collaborations, particularly successful CGT (cell and cistron therapies), are peculiarly babelike connected planetary cooperation. So far, I person not seen immoderate impact," JW Chief Executive Leo Tian told Reuters.

JW, whose largest shareholder is U.S. drugmaker Bristol ‌Myers Squibb done that firm's ​wholly owned subsidiary Juno Therapeutics, specializes ​in compartment immunotherapy ​products. Tian added that for assets successful ‌its pipeline JW was "actively seeking ​cooperations" with ​companies extracurricular China.

Reuters antecedently reported that China's blocking of Meta's acquisition of Manus would heighten the ​risk for planetary ‌investors looking to put successful precocious tech firms ​with ties to the country.

(Reporting by Andrew ​Silver; Editing by Gus Trompiz)